Please assess the completion status of the following clinical trial:

Trial Title: Omalizumab in Severe Asthmatics With Food Allergy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 6 - 18 years~* Severe persistent allergic asthma according to the GINA guidelines~* Sensitized to a perennial aeroallergen, as witnessed by positive skin test and/or in vitro reactivity~* Symptoms inadequately controlled with inhaled corticosteroids + another medication, as witnessed by an ACT ≤ 19~* On treatment with high dose inhaled corticosteroids + another medication. Threshold dose for inhaled corticosteroids set at 400 mcg/day budesonide (or equivalent doses) for children \< 12 years, at 800 mcg/day for older patients.~* Immediate food allergy with anaphylactic symptoms within 1hr. of ingestion of milk, egg, wheat, peanut, hazelnut, and/or codfish.~* Total IgE \< 70 and \>1,500 kU/L at baseline~* Sensitivity to food allergen documented by a positive skin prick test result and/or allergen-specific IgE level, with 0.35 kU/L as a lower limit of eligibility~* Positive OFC within the past 12 months, with minimal or no reactions to the placebo challenge.~* Trained on the proper use of epinephrine~* In case of female subjects of child-bearing potential, negative human chorionic gonadotropin blood sample for pregnancy testing~* No known contraindications to oral immunotherapy with food protein or Omalizumab~* Parent/legal guardian written informed consent~Exclusion Criteria:~* Total IgE at screening \> 70 or ≤ 2,500 kUI/L~* allergy to food(s) not investigated in this study~* Immune deficiency~* Previous reaction to Omalizumab~* Previous organ transplantation~* Use of monoclonal antibodies in the previous 6 months~* Subjects with gastrointestinal or gastroesophageal disease, chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic pulmonary disease.~* Subjects who have received an experimental drug in the last 30 days prior to admission into this study or who plan to use an experimental drug during the study~* Pregnant or breast-feeding females.~* Subjects with food protein induced enterocolitis syndrome (FPIES)~* Subjects is on a build-up phase of standard subcutaneous immunotherapy for inhalant allergens (may be enrolled on maintenance dose)~* Inability to discontinue antihistamines for 5 half-lives prior to routine study tests (OFC)~* Subjects with weight-IgE combination yielding a dose requirement greater than 600 mg according to the EMA schedule for Omalizumab~* Systemic steroids oral, IM, or IV for indications other than asthma for more than 3 weeks in the past 6 months.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Severe asthmatics with history of food anaphylaxis (Type: None): Omalizumab will be administered i.m. with doses ranging from 150 mg every 28 days to 600 mg every 14 days, according to EMA dosing range table.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete